Skip Navigation LinksOA_ADAP_Management_Memo_2020-28_Addition_of_Temixys_to_the_ADAP_Formulary

State of Cal Logo
EDMUND G. BROWN JR.
Governor

State of California—Health and Human Services Agency
California Department of Public Health


ADAP MM 2020-28
September 11, 2020


TO:
ADAP ENROLLMENT WORKERS

SUBJECT:
ADDITION OF LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE (TEMIXYS™) TO THE ADAP FORMULARY

​ADAP MANAGEMENT MEMO 2020-28: ADDITION OF LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE (TEMIXYS™) TO THE ADAP FORMULARY


Effective September 10, 2020, lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg, (Temixys™) has been added to the ADAP formulary. Temixys™ is a combination of two nucleoside analog reverse transcriptase inhibitors. Temixys™ is a once-daily single-tablet combination regimen used for the treatment of HIV-1 infection in combination with other antiretroviral medications. Temixys™ received federal Food and Drug Administration (FDA) approval in November 2018; however, it was not available in the U.S. until the last quarter of 2019. Temixys™ contains the same ingredients as Cimduo™, which is already on the ADAP formulary. The addition of Temixys™ will ensure that ADAP clients are not denied coverage due to the version of lamivudine/tenofovir disoproxil fumarate that is dispensed.

ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary has been updated to reflect the addition of Temixys™. Access to the updated formulary is available at the following URL: https://cdph.magellanrx.com/member/documents.

If you have any questions regarding the addition of this medication to the ADAP formulary, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.

Thank you,
Sandra_Robinson_E_Signature

Sandra Robinson, MBA
ADAP Branch Chief
California Department of Public Health


Page Last Updated :